Adaptimmune Therapeutics PLC (ADAPY) stock
ADAPYOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2025, quý kết thúc ngày Jun 30, 2025Last filing: 10-Q on Aug 13, 2025Score 3/30
$0.04+0.00 (+9.38%)
Close on Oct 19, 2026Market cap $55.46MP/E –Yield –
Adaptimmune Therapeutics price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Adaptimmune Therapeutics's price to sales ratio was 0.9× on Oct 19, 2026, against 1.2× a year earlier. Over the last 5 years it ranged from 0.1× to 438.9×, with a median of 13.8×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Oct 19, 2026 | 0.9× | +0.2 |
| 2025 | Dec 31, 2025 | 0.6× | −4.1 |
| 2024 | Dec 31, 2024 | 4.7× | −10.5 |
| 2023 | Dec 29, 2023 | 15.2× | −66.6 |
| 2022 | Dec 30, 2022 | 81.8× | −322.4 |
| 2019 | Dec 31, 2019 | 404.2× | +346.3 |
| 2018 | Dec 31, 2018 | 57.9× | −322.5 |
| 2017 | Dec 29, 2017 | 380.4× | +206.1 |
| 2016 | Dec 30, 2016 | 174.3× | −214.7 |
| 2015 | Nov 30, 2015 | 389.0× | – |
See a number that looks wrong?